Attovia Therapeutics, Inc.

NASDAQ:ATTO

Biotechnology

Healthcare
$15.53 -1.20%

-$0.18 today

Market cap
$709.92M
Beta
0.00
P/E (TTM)
-15.9
EPS (TTM)
-$0.86
52W Low $14.23High $28.00

Volume 0.34M

Average 0.45M

ATTO Total Non-current Liabilities

All obligations due after more than one year.

Attovia Therapeutics, Inc.NASDAQ: ATTO

Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026

Total non-current liabilities of $2.97M in Q2 FY2026

Q2 FY2026 total non-current liabilities was $2.97M.

Context

  • Total non-current liabilities amounted to 2.3% of total assets at the end of Q2 FY2026.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$2.97M-17.1% QoQ
Last fiscal yearDec 2025
$4.1M-40.3% YoY
Total Non-current Liabilities past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year-40.3%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Total Non-current Liabilities history

USD · from the balance sheet

Latest · FY2025
4.1M USD
Year-over-year change
-40.3%
1-year CAGR
-40.3%

Total Non-current Liabilities vs competitors

How ATTO compares with its peers on the latest reported figures

  • Peers report in different currencies, so total non-current liabilities is compared through growth and share of total assets rather than absolute size.
  • Total non-current liabilities amounts to 2.3% of total assets for ATTO, versus a peer median of 5.6%.
ATTO Competitors
Total Non-current Liabilities for ATTO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
ANABAnaptysBio, Inc.Mar 2026$275.24M USD-20.0%-3.6%83.5%
MLTXMoonLake ImmunotherapeuticsMar 2026$100.24M USD+34.2%+465.8%25.0%
ALMSAlumis Inc. Common StockJun 2026$32.23M USD-19.5%-49.5%5.7%
ACRSAclaris Therapeutics, Inc.Mar 2026$27.7M USD-14.8%-6.4%13.9%
AGMBAgomAb Therapeutics N.V. American Depositary SharesSep 2025€9.19M EUR——5.5%
EVMNEvommune, Inc.Mar 2026$7.3M USD-96.2%—2.3%
QTTBQ32 Bio Inc.Mar 2026$6.69M USD-90.2%-60.3%10.5%
ATTOAttovia Therapeutics, Inc.Jun 2026$2.97M USD——2.3%
ORKAOruka Therapeutics, Inc.Sep 2026$2.09M USD+40.3%+67.4%0.2%
CNTBConnect Biopharma Holdings LimitedDec 2025$482K USD-26.5%-18.7%0.9%
ZURAZura Bio LimitedMar 2026$0 USD——0.0%
Peer median (excluding ATTO) —-19.7%-6.4%5.6%

Competitors are the stored peer set for ATTO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Attovia Therapeutics, Inc.

NASDAQ:ATTO

Intrinsic Alpha fair value

Locked

Current Price

$15.53

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.